Alnylam initiated with a Peer Perform at Wolfe Research

Wolfe Research initiated coverage of Alnylam with a Peer Perform rating. Despite the optimism about HELIOS-B’s success, concerns include there’s limited upside but substantial downside risks due to revenue implications and commercial hurdles in the cardiomyopathy market, the analyst tells investors in a research note.